Benzinga
Benzinga
Benzinga
lunedì, settembre 28

Ascendis Pharma AS

ASNDNASDAQ
Trade with Public
Trade with Public
$230.01
4.411.96%
Ult. Agg.: Sep 28, 12:46 PM
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Ascendis Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascendis Pharma (ASND).

Price Target Range — 10 Quarters

Analyst Consensus — 19 Analysts

19Buy
Consensus RatingBuy# Analysts19Avg. Consensus PT$301Upside to Avg. PT+31.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 25, 2026Cantor FitzgeraldLi WatsekMaintainedOverweight$300
Sep 15, 2026Raymond JamesMartin AusterDowngradeStrong Buy→Outperform$287
More with Benzinga EdgeGet Access

Analyst Ratings News

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
Avi Kapoor

PRO
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved